

ALLERGAN INC  
Form 8-K  
January 21, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**January 21, 2014**

**Date of Report (Date of Earliest Event Reported)**

**ALLERGAN, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State of Incorporation)**

**1-10269**  
**(Commission File Number)**

**95-1622442**  
**(IRS Employer**

**Identification Number)**

**2525 Dupont Drive**

**Irvine, California 92612**

**(Address of Principal Executive Offices) (Zip Code)**

**(714) 246-4500**

**(Registrant's Telephone Number, Including Area Code)**

N/A

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The Board of Directors (the Board) of Allergan, Inc. (Allergan) increased the size of the Board from 9 to 10 members and elected Henri Termeer to fill the resulting vacancy and serve as a member of the Board, effective as of January 24, 2014. Mr. Termeer was also appointed to serve as a member of the Corporate Governance and Compliance Committee and the Organization and Compensation Committee, effective as of January 24, 2014.

Mr. Termeer will receive compensation in accordance with Allergan's non-employee director compensation practices described in Allergan's 2013 proxy statement, filed with the Securities and Exchange Commission on March 8, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLERGAN, INC.**

Date: January 21, 2014

By: /s/ Matthew J. Maletta

Name: Matthew J. Maletta

Title: Vice President,

Associate General Counsel and Secretary